
Journal Review in Breast Surgery: Evolution of DCIS Management
Behind The Knife: The Surgery Podcast
00:00
DCIS: A Non-Obligatory Precursor of Invasive Breast Cancer
Dr. Laura Esserman is a renowned breast surgical oncologist and co-leader of the UCSF Breast Oncology Program. She leads several innovative multi-center trials, including the ISPI-2 adaptive platform trial for stage two and three high-risk breast cancer. For patients with high-risk DCIS, she has designed a study of neo-agiment, inter-leasional pembrolizumab,. And an mRNA-based drug that encodes multiple cytokines to stimulate the tumor immune microenvironment.
Transcript
Play full episode